77 related articles for article (PubMed ID: 23658297)
1. Discovering what makes STAT signaling TYK in T-ALL.
Fontan L; Melnick A
Cancer Discov; 2013 May; 3(5):494-6. PubMed ID: 23658297
[TBL] [Abstract][Full Text] [Related]
2. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
[TBL] [Abstract][Full Text] [Related]
4. Oleanolic acid suppresses resistin induction in adipocytes by modulating Tyk-STAT signaling.
Kim HS; Sung HY; Kim MS; Kim JL; Kang MK; Gong JH; Park HS; Kang YH
Nutr Res; 2013 Feb; 33(2):144-53. PubMed ID: 23399665
[TBL] [Abstract][Full Text] [Related]
5. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
Curtis DJ
Br J Haematol; 2017 Apr; 177(2):169-170. PubMed ID: 28211568
[No Abstract] [Full Text] [Related]
8. [Notch signaling proteins and oncogenesis].
Gu F; Ma YJ; Fu L
Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):629-32. PubMed ID: 18070456
[No Abstract] [Full Text] [Related]
9. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
10. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
11. Tyk2 and signal transducer and activator of transcription 1 contribute to intestinal I/R injury.
Costantino G; Egerbacher M; Kolbe T; Karaghiosoff M; Strobl B; Vogl C; Helmreich M; Müller M
Shock; 2008 Feb; 29(2):238-44. PubMed ID: 17693920
[TBL] [Abstract][Full Text] [Related]
12. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.
Regis G; Icardi L; Conti L; Chiarle R; Piva R; Giovarelli M; Poli V; Novelli F
Leukemia; 2009 Nov; 23(11):2102-8. PubMed ID: 19626047
[TBL] [Abstract][Full Text] [Related]
13. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon.
Hazari S; Taylor L; Haque S; Garry RF; Florman S; Luftig R; Regenstein F; Dash S
Virol J; 2007 Sep; 4():89. PubMed ID: 17877826
[TBL] [Abstract][Full Text] [Related]
16. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
Waanders E; Scheijen B; Jongmans MC; Venselaar H; van Reijmersdal SV; van Dijk AH; Pastorczak A; Weren RD; van der Schoot CE; van de Vorst M; Sonneveld E; Hoogerbrugge N; van der Velden VH; Gruhn B; Hoogerbrugge PM; van Dongen JJ; Geurts van Kessel A; van Leeuwen FN; Kuiper RP
Leukemia; 2017 Apr; 31(4):821-828. PubMed ID: 27733777
[TBL] [Abstract][Full Text] [Related]
17. [Significance of microRNA-16 and bcl-2 expression in T lymphoblastic lymphoma/leukemia and its relation with prognosis].
Li J; Li P; Wang JF; Xi YF
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):748-52. PubMed ID: 24447552
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes.
Li W; Jiang Z; Li T; Wei X; Zheng Y; Wu D; Yang L; Chen S; Xu B; Zhong M; Jiang J; Hu Y; Su H; Zhang M; Huang X; Geng S; Weng J; Du X; Liu P; Li Y; Liu H; Yao Y; Li P
Mol Cancer; 2015 Feb; 14():26. PubMed ID: 25644173
[TBL] [Abstract][Full Text] [Related]
19. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
[TBL] [Abstract][Full Text] [Related]
20. Activating TCR Signaling to Thwart T-ALL.
Lemonnier F; Mak TW
Cancer Discov; 2016 Sep; 6(9):946-8. PubMed ID: 27587465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
